Sichuan Kelun-Biotech Gains Approval for H Share Circulation

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the Hong Kong Stock Exchange for the full circulation of its H shares. This approval allows the conversion of 25,421,196 domestic shares into H shares, increasing the proportion of H shares in the company’s total share capital from 57.83% to 69.02%. This strategic move is expected to enhance the company’s market liquidity and potentially attract more international investors, reflecting positively on its market positioning.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of biopharmaceutical products, with a market focus on both domestic and international stakeholders.

YTD Price Performance: 71.95%

Average Trading Volume: 517,801

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$59.19B

For an in-depth examination of 6990 stock, go to TipRanks’ Stock Analysis page.